Argenx sales expand as additional clinical and regulatory work advances
Argenx ($ARGX) reported third-quarter 2026 product sales of approximately $1.7 billion, an increase of 54% from a year earlier and 13% from the preceding quarter. Net profit attributable to shareholders increased to $506 million from $344 million. Continued commercial expansion of VYVGART supports the funding base for its autoimmune-disease development program. The company reported a supplemental application for ocular myasthenia gravis and plans to submit its immune-mediated necrotizing myopath
0